>
Renalytix logo

RENX - Renalytix Share Price

886p 36.0  4.2%

Last Trade - 4:37pm

Sector
Technology
Size
Mid Cap
Market Cap £614.0m
Enterprise Value £560.1m
Revenue £291k
Position in Universe 561st / 1785
Bullish
Bearish
Unlock RENX Revenue
Momentum
Relative Strength (%)
1m +26.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 2.30 34.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, RenalytixPLC revenues increased from $0K to $400K. Net lossincreased from $5.6M to $14M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsAdministrative expenses increase from $5M to $14M (expense), Finance income - net Loss before tax increase of 66% to$2.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RENX
Graphical History

Revenue

RENX Revenue Unlock RENX Revenue

Net Income

RENX Net Income Unlock RENX Revenue

Normalised EPS

RENX Normalised EPS Unlock RENX Revenue

PE Ratio Range

RENX PE Ratio Range Unlock RENX Revenue

Dividend Yield Range

RENX Dividend Yield Range Unlock RENX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RENX EPS Forecasts Unlock RENX Revenue
Profile Summary

Renalytix plc, formerly Renalytix AI plc, is an artificial intelligence-enabled in vitro diagnostics company. The Company's diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated March 15, 2018
Public Since November 6, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Technology
Industry Software & IT Services
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 72,240,706
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RENX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RENX
Upcoming Events for RENX
Thursday 21st October, 2021
Q4 2021 Renalytix PLC Earnings Release
Thursday 21st October, 2021
Q4 2021 Renalytix PLC Earnings Call
Tuesday 7th December, 2021 Estimate
Renalytix AI PLC Annual Shareholders Meeting
Frequently Asked Questions for Renalytix
What is the Renalytix share price?

As of 4:37pm, shares in Renalytix are trading at 886p, giving the company a market capitalisation of £614.0m. This share price information is delayed by 15 minutes.

How has the Renalytix share price performed this year?

Shares in Renalytix are currently trading at 886p and the price has moved by 84.78% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Renalytix price has moved by 49.6% over the past year.

What are the analyst and broker recommendations for Renalytix?

Of the analysts with advisory recommendations for Renalytix, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Renalytix is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Renalytix next release its financial results?

Renalytix is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Renalytix dividend yield?

Renalytix does not currently pay a dividend.

Does Renalytix pay a dividend?

Renalytix does not currently pay a dividend.

When does Renalytix next pay dividends?

Renalytix does not currently pay a dividend.

How do I buy Renalytix shares?

To buy shares in Renalytix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Renalytix?

Shares in Renalytix are currently trading at 886p, giving the company a market capitalisation of £614.0m.

Where are Renalytix shares listed? Where are Renalytix shares listed?

Here are the trading details for Renalytix:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: RENX
What kind of share is Renalytix?

Based on an overall assessment of its quality, value and momentum, Renalytix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Renalytix share price forecast 2021?

Shares in Renalytix are currently priced at 886p. At that level they are trading at 0.125% discount to the analyst consensus target price of 887.11.

Analysts covering Renalytix currently have a consensus Earnings Per Share (EPS) forecast of -0.5091100711 for the next financial year.

How can I tell whether the Renalytix share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renalytix. Over the past six months, the relative strength of its shares against the market has been -12.02%. At the current price of 886p, shares in Renalytix are trading at -10.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Renalytix PE Ratio?

We were not able to find PE ratio data for Renalytix.

Who are the key directors of Renalytix?

We were unable to find the directors for Renalytix.

Who are the major shareholders of Renalytix?

Here are the top five shareholders of Renalytix based on the size of their shareholding:

Icahn School of Medicine at Mount Sinai Corporation
Percentage owned: 14.88% (10.8m shares)
Mills (Christopher Harwood Bernard) Individual Investor
Percentage owned: 12.7% (9.17m shares)
McCullough (James) Individual Investor
Percentage owned: 3.79% (2.74m shares)
Canaccord Genuity Wealth Management Investment Advisor/Hedge Fund
Percentage owned: 3.48% (2.52m shares)
Amati Global Investors Limited Investment Advisor
Percentage owned: 3.4% (2.46m shares)
Similar to RENX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.